Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
Miller D, Fox R, Phillips J, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott C, Tozer D, MacManus D, Yousry T, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson K, Fox R, Phillips J, Hutchinson M, Havrdova E, Kita M, Wilson K, Yang M, Dawson K, Antel J, Ware J, Polman C, Kowey P, Chung R, Bakris G, Richert J, Seibert B, Brandes D, Brassat D, Cohen B, Diem R, Goldman M, Herndon R, Miller A, Tumani H, Alfaro-Vidal T, Crespo C, Foster J, Hunter K, Garcia-Gomez A, MacManus D, Miller D, Santana V, Tozer D, Wheeler-Kingshott C, Yousry T, Kneebone C, Fedulau A, Likhachev S, Mikhailova E, Naumova H, Decoo D, Gaer L, Sindic C, Grgic S, Sinanovic O, Suljic E, Deleva N, Georgiev D, Haralanov L, Ivanova S, Manchev I, Minchev D, Stamenova P, Tournev I, Vacheva E, Zahariev Z, Bar-Or A, Blevins G, Kremenchutzky M, Veloso F, Witt N, Vargas Howell R, Vindas A, Habek M, Rudež J, Soldo-Butković S, Vurdelja R, Doležil D, Havrdova E, Nova'k J, Vaclavik D, Antsov K, Gross-Paju K, Haldre S, Palu A, Toomsoo T, Al Khedr A, Camu W, Debouverie M, Defer G, De Seze J, Labauge P, Moreau T, Pelletier J, Rumbach L, Daskalovska V, Angnstwurm K, Benes H, Berthele A, Boldt H, Christopher A, Derfuß T, Eisensehr I, Emrich P, Feneberg W, Hoffmann F, Hohlfeld R, Hüntemann R, Kallmann B, Kieseier B, Landefeld H, Lüer W, Masri S, Nelles G, Oschmann P, Paschen C, Reifschneider G, Sailer M, Schimrigk S, Spiegel-Meixensberger M, Storch-Hagenlocher B, Tackenberg B, Tiel-Wilck K, Karageorgiou C, Papathanasopoulos P, Thomaides T, Vlaikidis N, Arjundas D, Behari M, Ghosh A, Ghosh P, Ichaporia N, Khurana D, Kulkarni R, Kumar S, Mehndiratta M, Mehta N, Misra U, Mukherji J, Nellikunja S, Salem A, Sethi P, Shah S, Singh G, Singh M, Singh Y, Srinivasa R, Vijayan K, Hutchinson M, Sweeney B, Gilad R, Shahien R, Paegle A, Delgado C, Escamilla J, Estañol B, Lopez M, Macias M, Punzo G, Quiñones S, Renteria M, Santos J, Gavriliuc M, Groppa S, Odainic O, Timmings P, Czlonkowska A, Dorobek M, Drozdowski W, Fryze W, Hertmanowska H, Kaminska A, Kapelusiak-Pielok M, Kleczkowska M, Kochanowicz J, Losy J, Nowacki P, Nyka W, Pierzchala K, Podemski R, Potemkowski A, Selmaj K, Stelmasiak Z, Szczudlik A, Tutaj A, Wajgt A, Zielinski T, Balasa R, Ionescu-Dimancea V, Mihancea P, Popescu C, Protosevici L, Miletić Drakulić S, Nadj C, Raicevic R, Vojinovic S, Kahancová E, Kurca E, Lisý L, Turčáni P, Arroyo R, Fernández O, Guijarro C, Izquierdo G, Lopez F, Montalbán X, Oreja-Guevara C, Prieto J, Buchakchyys'ka N, Chmyr G, Goloborodko A, Kobys T, Kushnir G, Lebedynets V, Lytvynenko N, Moskovko S, Nehrych T, Palamar B, Pasyura I, Ryabichenko T, Voloshina N, Apperson M, Applebee A, Asher S, Ayala R, Ayres D, Azizi S, Baker M, Bauer B, Bomprezzi R, Buckler R, Carlini W, Chinea A, Cohan S, Crowell G, Edwards K, Eubank G, Felton W, Fodor P, Foley J, Ford C, Fox E, Fox R, Forester M, Freedman S, Garmany G, Gazda S, Giang D, Glaun B, Gold S, Gottesman M, Gudesblatt M, Herbert J, Herskowitz A, Honeycutt W, Huddlestone J, Hull R, Hunter S, Hutton G, Jacobs D, Janicki M, Khatri B, Kinkel R, Kita M, Krolczyk S, Krupp L, LaGanke C, Levin M, Licht J, Luzzio C, Lynch S, Mattson D, Mikol D, Miller T, Minagar A, Mitchell G, Moses H, Negroski D, Newman S, Pardo G, Patel M, Perel A, Phillips J, Picone M, Rammohan K, Rao T, Rinker J, Sadiq S, Schaeffer J, Sheremata W, Shin R, Shubin R, Silverman S, Smith R, Stein L, Stein M, Steiner D, Steingo B, Sullivan H, Sunter W, Vaishnav A, Vasquez A, Voci J, Warach J, Weinstock-Guttman B, Williams M, Wray S. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 2015, 84: 1145-1152. PMID: 25681448, PMCID: PMC4371413, DOI: 10.1212/wnl.0000000000001360.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisDelayed-release dimethyl fumarateMagnetization transfer ratioLesion activityEffects of delayed-release dimethyl fumarateMultiple sclerosisVolume of T2-hyperintensityActive lesion countsSubcutaneous glatiramer acetatePlacebo-controlled studyMRI lesion activityT2 hyperintense lesionsDimethyl fumarateMagnetization transfer ratio changesT1-hypointense lesionsYear of treatmentClass I evidenceInflammatory lesion activitySafety of DMFDMF BIDDMF therapyOral fumarateGd+ lesionsGadolinium enhancementGlatiramer acetate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply